questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Utilisations thérapeutiques
Antinéoplasiques
Agonistes myélo-ablatifs
Agonistes myélo-ablatifs : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Biopsie de la moelle osseuse
Tests sanguins
Imagerie médicale
Fonction hépatique
Marqueurs tumoraux
Anomalies hématologiques
Évaluation de la moelle osseuse
Tests de fonction hématologique
Symptômes
5
Nausées
Immunosuppression
Prévention
5
Effets secondaires
Suivi médical
Soutien psychologique
Anxiété
Traitements
5
Chimiothérapie
Greffe de moelle osseuse
Greffe de cellules souches
Préparation myélo-ablatif
Busulfan
Cyclophosphamide
Surveillance médicale
Complications
Gestion de la douleur
Soutien psychologique
Complications
5
Saignement
Thrombocytopénie
Anémie
Transfusions sanguines
Troubles hématologiques
Cancer secondaire
Facteurs de risque
5
Cancers hématologiques
Antécédents médicaux
Mutations génétiques
Prédisposition
Radiothérapie
Chimiothérapie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Agonistes myélo-ablatifs : Questions médicales les plus fréquentes",
"headline": "Agonistes myélo-ablatifs : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Agonistes myélo-ablatifs : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-12",
"dateModified": "2026-04-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Agonistes myélo-ablatifs"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antinéoplasiques",
"url": "https://questionsmedicales.fr/mesh/D000970",
"about": {
"@type": "MedicalCondition",
"name": "Antinéoplasiques",
"code": {
"@type": "MedicalCode",
"code": "D000970",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.248"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Agonistes myélo-ablatifs",
"alternateName": "Myeloablative Agonists",
"code": {
"@type": "MedicalCode",
"code": "D019653",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elizabeth J Shpall",
"url": "https://questionsmedicales.fr/author/Elizabeth%20J%20Shpall",
"affiliation": {
"@type": "Organization",
"name": "Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas."
}
},
{
"@type": "Person",
"name": "Richard E Champlin",
"url": "https://questionsmedicales.fr/author/Richard%20E%20Champlin",
"affiliation": {
"@type": "Organization",
"name": "Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas."
}
},
{
"@type": "Person",
"name": "Qaiser Bashir",
"url": "https://questionsmedicales.fr/author/Qaiser%20Bashir",
"affiliation": {
"@type": "Organization",
"name": "Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas."
}
},
{
"@type": "Person",
"name": "Amin M Alousi",
"url": "https://questionsmedicales.fr/author/Amin%20M%20Alousi",
"affiliation": {
"@type": "Organization",
"name": "Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas."
}
},
{
"@type": "Person",
"name": "Chitra Hosing",
"url": "https://questionsmedicales.fr/author/Chitra%20Hosing",
"affiliation": {
"@type": "Organization",
"name": "Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Role of Microsurgery in Burn Surgery.",
"datePublished": "2024-04-01",
"url": "https://questionsmedicales.fr/article/38789149",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cps.2024.02.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Microsurgery Robots: Applications, Design, and Development.",
"datePublished": "2023-10-16",
"url": "https://questionsmedicales.fr/article/37896597",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/s23208503"
}
},
{
"@type": "ScholarlyArticle",
"name": "Robotic microsurgery for pediatric peripheral nerve surgery.",
"datePublished": "2024-10-29",
"url": "https://questionsmedicales.fr/article/39470931",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11701-024-02140-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Robotic Microsurgery in Plastic and Reconstructive Surgery: A Literature Review.",
"datePublished": "2023-07-25",
"url": "https://questionsmedicales.fr/article/37490999",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/15533506231191211"
}
},
{
"@type": "ScholarlyArticle",
"name": "Low-fidelity simulation models in urology resident's microsurgery training.",
"datePublished": "2023-12-01",
"url": "https://questionsmedicales.fr/article/38055400",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/acb386523"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antinéoplasiques",
"item": "https://questionsmedicales.fr/mesh/D000970"
},
{
"@type": "ListItem",
"position": 6,
"name": "Agonistes myélo-ablatifs",
"item": "https://questionsmedicales.fr/mesh/D019653"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Agonistes myélo-ablatifs - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Agonistes myélo-ablatifs",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-26",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Agonistes myélo-ablatifs",
"description": "Comment diagnostiquer une nécessité d'agonistes myélo-ablatifs ?\nQuels examens sont nécessaires avant traitement ?\nQuels marqueurs indiquent un traitement myélo-ablatif ?\nComment évaluer l'état de la moelle osseuse ?\nQuels symptômes justifient un traitement myélo-ablatif ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Microsurgery#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Agonistes myélo-ablatifs",
"description": "Quels sont les symptômes d'une moelle osseuse affectée ?\nComment se manifeste l'anémie liée à la myélo-ablation ?\nQuels signes indiquent une infection après traitement ?\nQuels symptômes peuvent survenir après une myélo-ablation ?\nComment reconnaître une hémorragie liée à la myélo-ablation ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Microsurgery#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Agonistes myélo-ablatifs",
"description": "Comment prévenir les complications après myélo-ablation ?\nQuelles mesures prendre pour éviter les infections ?\nComment gérer les effets secondaires des agonistes ?\nQuels conseils nutritionnels sont recommandés ?\nComment le soutien psychologique aide-t-il ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Microsurgery#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Agonistes myélo-ablatifs",
"description": "Quels traitements sont associés aux agonistes myélo-ablatifs ?\nComment se déroule une greffe après myélo-ablation ?\nQuels médicaments sont utilisés comme agonistes myélo-ablatifs ?\nQuelle est l'importance de la surveillance post-traitement ?\nQuels soins de soutien sont nécessaires après traitement ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Microsurgery#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Agonistes myélo-ablatifs",
"description": "Quelles sont les complications possibles des agonistes myélo-ablatifs ?\nComment reconnaître une infection post-myélo-ablation ?\nQuels sont les risques de saignement après traitement ?\nComment gérer une anémie post-myélo-ablation ?\nQuelles sont les conséquences à long terme des agonistes ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Microsurgery#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Agonistes myélo-ablatifs",
"description": "Quels facteurs augmentent le besoin d'agonistes myélo-ablatifs ?\nComment l'âge influence-t-il le traitement ?\nQuels facteurs génétiques sont impliqués ?\nComment le mode de vie affecte-t-il le risque ?\nQuels antécédents médicaux sont des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Microsurgery#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une nécessité d'agonistes myélo-ablatifs ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, biopsies de moelle osseuse et évaluation clinique."
}
},
{
"@type": "Question",
"name": "Quels examens sont nécessaires avant traitement ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens d'imagerie, des analyses sanguines et une évaluation de la fonction hépatique sont requis."
}
},
{
"@type": "Question",
"name": "Quels marqueurs indiquent un traitement myélo-ablatif ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs tumoraux spécifiques et des anomalies hématologiques peuvent indiquer ce besoin."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'état de la moelle osseuse ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie de moelle osseuse et des tests de fonction hématologique sont utilisés pour l'évaluation."
}
},
{
"@type": "Question",
"name": "Quels symptômes justifient un traitement myélo-ablatif ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes tels que l'anémie sévère, les infections récurrentes ou des hémorragies inexpliquées peuvent justifier ce traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une moelle osseuse affectée ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, infections fréquentes, ecchymoses et saignements anormaux."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'anémie liée à la myélo-ablation ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'anémie se manifeste par une fatigue accrue, des palpitations et une pâleur de la peau."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une infection après traitement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes tels que fièvre, frissons, et malaise général peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent survenir après une myélo-ablation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des nausées, vomissements, et une immunosuppression peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hémorragie liée à la myélo-ablation ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements inhabituels, des ecchymoses et des saignements de nez fréquents sont des signes."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications après myélo-ablation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut des soins d'hygiène rigoureux et des vaccinations appropriées."
}
},
{
"@type": "Question",
"name": "Quelles mesures prendre pour éviter les infections ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les foules, se laver les mains fréquemment et porter un masque en cas de besoin."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires des agonistes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des effets secondaires passe par des médicaments symptomatiques et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels conseils nutritionnels sont recommandés ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, riche en protéines et en vitamines, est recommandée pour la récupération."
}
},
{
"@type": "Question",
"name": "Comment le soutien psychologique aide-t-il ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le soutien psychologique aide à gérer l'anxiété et le stress liés au traitement et à la maladie."
}
},
{
"@type": "Question",
"name": "Quels traitements sont associés aux agonistes myélo-ablatifs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et les greffes de moelle osseuse."
}
},
{
"@type": "Question",
"name": "Comment se déroule une greffe après myélo-ablation ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La greffe implique la transplantation de cellules souches après une préparation myélo-ablatif."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés comme agonistes myélo-ablatifs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des agents comme le busulfan et la cyclophosphamide sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la surveillance post-traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance est cruciale pour détecter les complications et ajuster le traitement si nécessaire."
}
},
{
"@type": "Question",
"name": "Quels soins de soutien sont nécessaires après traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins de soutien incluent la gestion de la douleur, la nutrition et le soutien psychologique."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des agonistes myélo-ablatifs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'infection, l'anémie, et des troubles de la coagulation."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection post-myélo-ablation ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme fièvre, frissons et fatigue intense peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de saignement après traitement ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques de saignement augmentent en raison de la thrombocytopénie induite par le traitement."
}
},
{
"@type": "Question",
"name": "Comment gérer une anémie post-myélo-ablation ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion de l'anémie peut nécessiter des transfusions sanguines et des suppléments de fer."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences à long terme des agonistes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences peuvent inclure des troubles hématologiques chroniques et des risques de cancer secondaire."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le besoin d'agonistes myélo-ablatifs ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de cancers hématologiques et des traitements antérieurs augmentent ce besoin."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients plus âgés peuvent avoir un risque accru de complications et une tolérance réduite."
}
},
{
"@type": "Question",
"name": "Quels facteurs génétiques sont impliqués ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mutations génétiques spécifiques peuvent prédisposer à des maladies nécessitant une myélo-ablation."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie malsain, comme le tabagisme, peut augmenter le risque de cancers hématologiques."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont des facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de radiothérapie ou de chimiothérapie augmentent le risque de complications."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 03/04/2026
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
4 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: upopat@mdanderson.org.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Hôpital Universitaire Robert-Debré, Paris, France; Paediatric Disease Working Party of European Society for Blood and Marrow Transplantation.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology, Ohio State University, Columbus, Ohio, USA.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Adult Bone Marrow Transplant Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Center for International Blood and Marrow Transplant Research, and.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Publications dans "Agonistes myélo-ablatifs" :
Acute burn reconstruction involves intricate strategies such as skin grafting and innovative technologies, addressing challenges in coverage and minimizing donor site morbidity. Despite being rarely u...
Microsurgical techniques have been widely utilized in various surgical specialties, such as ophthalmology, neurosurgery, and otolaryngology, which require intricate and precise surgical tool manipulat...
The technology of microsurgical robotic systems has shown potential benefit during the last decade for a variety of microsurgical procedures, such as vascular anastomoses, lymphatic anastomoses or ner...
Surgical robots have innovated the microsurgical field by providing advantages that improve surgical performance. These robots have been adopted by certain specialties more than others. This study dis...
This study is a literature review of articles investigating "robotic microsurgery in plastic and reconstructive surgery" using the PubMed database and the Cochrane Library....
A total of nineteen relevant articles were found and 5 articles performed a direct comparison between the robotic and manual approaches. Longer operating times were reported in the robotic groups feat...
While the results provide an outlook into the outcome of robotic platforms in this field, current research is limited and further studies are required to provide a fundamental analysis....
To evaluate the gain of microsurgical skills and competencies by urology residents, using low-fidelity experimental models....
The study involved the use of training boards, together with a low-fidelity microsurgery simulator, developed using a 3D printer. The model consists in two silicone tubes, coated with a resin, measuri...
There was a decrease in the time needed to perform the anastomosis (p=0.0019), as well as a progressive increase in the score in the OSATS over during sessions S1 to S4. At S5, there was a slightly de...
The low-fidelity simulation was able to guarantee urology residents a solid gain in skills and competencies in microsurgery....
In robot-assisted microsurgery (RAMS), surgeons often face the challenge of operating with minimal feedback, particularly lacking in haptic feedback. However, most traditional desktop haptic devices h...
This study was aimed at evaluating the clinical and radiological outcomes of novel dynamic navigation (DN)-aided endodontic microsurgery (EMS), with an analysis of potential prognostic factors....
Forty-six teeth from 32 patients who received DN-aided EMS were included. Clinical and radiographic assessments were performed at least 1 year postoperatively. Two calibrated endodontists assessed rad...
Of the 32 patients with 46 treated teeth, 28 with 40 teeth were available for follow-up. Of the 28 patients, four (five teeth) refused to undergo CBCT and only underwent clinical and PA examinations, ...
DN-aided EMS has a favorable prognosis and could be considered an effective and reliable treatment strategy. Further investigations with larger sample sizes are required to confirm these results....
DN-aided EMS could be considered an effective and reliable treatment strategy....
classical models of microsurgical anastomosis training are expensive and have ethical implications. Some alternatives join low cost and easiness to store. However, the translation of knowledge acquire...
10 neurosurgery residents performed an end-to-end anastomosis in a 2-3mm placenta artery. The anastomoses were evaluated quantitatively, recording time; and qualitatively, applying a validated score (...
we observed a 17min reduction in the mean time to perform the anastomosis in the placenta model after the training in the konjac (p<0.05). There was a non-significant 20% reduction in gross leakage, b...
we demonstrate a reduction in anastomosis performing time in placental arteries after training sessions in the konjac noodle model, which can be regarded as a feasible low-cost method, particularly us...
Free flap transfer (FFT) is essential in soft tissue reconstruction and can be done under local anesthesia. However, there is no study evaluating the feasibility of FFT without hospitalization. This s...
Patients who underwent day microsurgery were included. The FFT was performed under local infiltration and/or block anesthesia without sedation by a surgeon with enough experience in supermicrosurgery....
Seventeen patients with a mean age of 40.4 years were included. All defects were of the upper extremity and due to trauma. Utilized anesthesia included local infiltration in 11 sites, digital block in...
FFT could safely be performed without hospitalization in selected cases of an upper extremity defect. Supermicrosurgery and careful patient selection play an important role in safe day microsurgery....
This study aims to create a synthetic laryngeal microsurgery simulation model and training program; to assess its face, content, and construct validity; and to review the available phonomicrosurgery s...
Nonrandomly assigned control study....
Simulation training course for the otolaryngology residency program at Pontificia Universidad Católica de Chile....
Resident (postgraduate year 1 [PGY1]/PGY2) and expert groups were recruited. A laryngeal microsurgery synthetic model was developed. Nine tasks were designed and assessed through a set of programmed e...
Eighteen participants were recruited (14 residents and 4 experts). Experts performed significantly better than residents in the SRS (p = .003), and GRS (p = .004). Internal consistency was demonstrate...
The face, content, and construct validity of the laryngeal microsurgery simulation training program were established. It could be replicated and incorporated into residents' curricula....